SAMANTHA NICE: Open Payments
NPI 1497424071 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,222 in 76 payments from 18 companies in 2025. Trend: 2023 $1,271 · 2024 $1,096 · 2025 $1,222
Food & beverage: $1,222
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $165 |
| ABBVIE INC. | 7 | $135 |
| Ipsen Biopharmaceuticals, Inc | 4 | $98 |
| Phathom Pharmaceuticals, Inc. | 10 | $73 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| GENZYME CORPORATION | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Gilead Sciences, Inc. | 2 | $46 |
| Madrigal Pharmaceuticals | 2 | $45 |
Products named: TREMFYA, ENTYVIO, DUPIXENT, IQIRVO, VOQUEZNA, XIFAXAN, REZDIFFRA, RINVOQ.
Industry payments across NE — which companies pay providers there.
